Hepko-V5 Cancer Vaccine Boosts Survival Rates in Advanced Liver Cancer Patients, Mongolian Study Finds
Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial.